Background/purpose: This study systematically reviews and analyzes the efficacy of Biodentine and Mineral Trioxide Aggregate (MTA) in primary tooth pulpotomy. Both materials are known for their biocompatibility, antimicrobial properties, and ability to maintain pulp vitality. Biodentine, introduced as a faster-setting and cost-effective alternative to MTA, is particularly advantageous in pediatric dentistry. Materials and methods: Data from randomized controlled trials (2010-2023) were analyzed, focusing on clinical and radiographic success rates at 6, 12, 18, and 24 months. Results: Results showed no significant differences between Biodentine and MTA in clinical success rates (e.g., 6 months: RR = 1.00, 95% CI: 0.98-1.03, P = 0.92) or radiographic success rates (e.g., 6 months: RR = 0.99, 95% CI: 0.97-1.02, P = 0.56). Additionally, rates of root resorption and pulp canal obliteration were comparable across follow-up periods. Conclusions: The findings confirm that Biodentine and MTA are equally effective for primary tooth pulpotomy. Biodentine's advantages, including faster setting time and reduced discoloration, make it a practical alternative. Future studies should explore long-term outcomes and patient satisfaction to further refine evidence-based clinical guidelines.